Unfortunately, safety signals in the form of ALT/AST elevations were identified in this ALERT trial, and likely played a key role in the decision of the sponsor (Centessa) to discontinue lixivaptan’s development in this area, terminating the phase III trials in ADPKD at early stages (Centessa Pharmaceuticals 2022). The gene discussed is GPT; the disease is autosomal dominant polycystic kidney disease.